In-market Utilisation of Liraglutide Used for Weight Management in Europe: a Retrospective Medical Record Review Study.

Registration

Registration

NCT02967757

Study type

OBSERVATIONAL

Status

COMPLETED

Enrollment

316

Start

2016-12-22

Primary completion

2019-05-28

Lead sponsor

Novo Nordisk A/S

Conditions

Metabolism and Nutrition Disorder; Obesity

Interventions

DRUG:liraglutide

Results posted

FALSE

Secondary identifiers

OTHER:U1111-1185-3661; REGISTRY:EUPAS16225

Registered primary outcomes

• Number of patients with BMI above or equal to 30 kg/m^2 [Less than 6 months before date of first prescription]
• Number of patients with BMI above or equal to 27kg/m^2 and below 30 kg/m^2 and 1 or more comorbidity [Less than 6 months before date of first prescription]
• Number of patients with above or equal to 27 kg/m^2 and below 30 kg/m^2 and no comorbidities [Less than 6 months before date of first prescription]
• Number of patients with BMI below 27 kg/m^2 [Less than 6 months before date of first prescription]
• Number of patients with BMI not measured [Within 6 months before date of the first prescription]